Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2Recruiting 2Completed 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Conditions

Neoplasms 2012Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 967Neoplasm Metastasis 902Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Lymphoma, Non-Hodgkin 659Prostatic Neoplasms 657Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 486Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 387Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 357Lymphoma, Mantle-Cell 345Glioma 343

Interventions

pembrolizumab 1Sirolimus 1Nivolumab 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Cancers × Clear all
NCT07092748 2025-07-30

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

Zhejiang Hisun Pharmaceutical Co. Ltd.

Phase 1 Recruiting
110 enrolled

Advanced Solid Cancers

NCT06710158 2025-07-29

Study of SC-102 in Patients With Advanced Solid Tumors

Tianjin ConjuStar Biologics Co., Ltd.

Phase 1 Recruiting
120 enrolled

Advanced Solid Cancers

NCT03956680 2025-02-19

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Bristol-Myers Squibb

Phase 1 Completed
54 enrolled

Advanced Solid Cancers

NCT03254732 2022-04-27

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Polaris Group

Phase 1 Terminated
33 enrolled

Advanced Solid Cancers

NCT00337376 2014-01-14

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Yale University

Phase 1 Terminated
23 enrolled

Advanced Solid Cancers

NCT01019941 2010-12-16

126ASC08Q

Chong Kun Dang Pharmaceutical

Phase 1 Completed
44 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡